Human monoclonal antibody (mAb) isotypes against human CD27
InvivoGen provides a family of anti-hCD27-derived monoclonal antibodies (mAbs) in multiple human isotypes.
They feature:
- the variable region of varlilumab targeting the human cluster of differentiation 27 (hCD27)
- a constant region that mediates different effector functions depending on the isotype.
The effector functions of the human isotypes in this family include antibody‑dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). You may choose between:
— IgG1 for high effector functions
(Anti-hCD27-hIgG1 is the biosimilar of the clinical antibody varlilumab),
— IgG1fut for even higher effector functions
(engineered non-fucosylated (fut) constant region), or
— IgG1NQ for no effector functions
(engineered N-glycosylation mutated constant region).
InvivoGen's mAbs have been generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography.
Key features of the Anti-hCD27 isotype family
- Clinically-relevant variable region targeting human CD27 (varlilumab)
- Choice of different constant regions for high/low effector functions
- Functionally validated by flow cytometry and ELISA
- The absence of bacterial contamination has been confirmed
Varlilumab is a fully human agonist anti-CD27-hIgG1 mAb that activates the costimulatory molecule CD27 [1]. This receptor is constitutively expressed on the majority of mature T cells. In the appropriate context of T cell receptor engagement, the interaction of CD27 with its ligand CD70 (also known as CD27L) promotes T cell activation, maturation of effector capacity, and T cell memory [1-2]. This interaction became of interest to immunologists as a co-stimulatory immune checkpoint (IC) molecule and is the target of an anti-cancer drug in clinical trials [2].
References:
1. Vitale LA, et al.,2012. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res.;18(14):3812-21.
2. Sanborn RE, et al., 2022 Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer.;10(8):e005147.
